Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The invention concerns adult multipotent human stem cells, characterized in that they have: i) significant telomerase activity, ii) an HLA Class I negative phenotype, iii) a normal karyotype, iv) a capacity to become quiescent, v) a capacity for self-renewal preserved for at least 130 population doublings.

Abstract: The invention concerns adult multipotent human stem cells, characterized in that they have:

Abstract: The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-&agr; receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.

Abstract: The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-.alpha. receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.

Abstract: The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-.alpha. receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.